Comparative Pharmacology
Head-to-head clinical analysis: ALBUTEROL versus ALBUTEROL SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALBUTEROL versus ALBUTEROL SULFATE.
ALBUTEROL vs ALBUTEROL SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing intracellular cyclic AMP, leading to bronchodilation.
Beta-2 adrenergic receptor agonist resulting in bronchodilation via increased cyclic AMP synthesis and smooth muscle relaxation.
2.5 mg (0.5 mL of 0.5% solution) via nebulization every 4-6 hours as needed; or 1-2 inhalations (90 mcg/inhalation) from a metered-dose inhaler every 4-6 hours as needed.
2 puffs (90 mcg/puff) via metered-dose inhaler q4-6h as needed; or 2.5 mg via nebulization q4-6h as needed
None Documented
None Documented
Terminal elimination half-life is 3.8-6.0 hours. In patients with asthma, the half-life is similar, but clinical effect duration is shorter due to rapid redistribution from the receptor site.
Terminal elimination half-life is 3.8–6 hours after inhalation; in patients with hepatic impairment, half-life may be prolonged up to 8 hours.
Primarily renal: approximately 60-70% of the dose is excreted in urine as unchanged drug and metabolites (sulfate conjugate) within 24 hours. Fecal excretion accounts for less than 10%.
Approximately 72% of an inhaled dose is recovered in urine as unchanged drug and metabolites (28% as sulfate conjugate) within 24 hours; fecal elimination accounts for less than 10%.
Category C
Category C
Beta-2 Adrenergic Agonist (Bronchodilator)
Beta-2 Adrenergic Agonist (Bronchodilator)